PGEN Stock Overview
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.94|
|52 Week High||US$11.10|
|52 Week Low||US$3.42|
|1 Month Change||-18.43%|
|3 Month Change||-36.96%|
|1 Year Change||-52.18%|
|3 Year Change||-57.73%|
|5 Year Change||-87.08%|
|Change since IPO||-84.07%|
Recent News & Updates
Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher
Shareholders in Precigen, Inc. ( NASDAQ:PGEN ) may be thrilled to learn that the analysts have just delivered a major...
|PGEN||US Biotechs||US Market|
Return vs Industry: PGEN underperformed the US Biotechs industry which returned 4.1% over the past year.
Return vs Market: PGEN underperformed the US Market which returned 20% over the past year.
|PGEN Average Weekly Movement||8.3%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: PGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PGEN's weekly volatility (8%) has been stable over the past year.
About the Company
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium.
Precigen Fundamentals Summary
|PGEN fundamental statistics|
Is PGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PGEN income statement (TTM)|
|Cost of Revenue||US$105.04m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.54|
|Net Profit Margin||-112.56%|
How did PGEN perform over the long term?See historical performance and comparison
Is Precigen undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PGEN is overvalued based on its PB Ratio (6.2x) compared to the US Biotechs industry average (2.8x).
How is Precigen forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PGEN's revenue (12.8% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: PGEN's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PGEN is forecast to be unprofitable in 3 years.
How has Precigen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PGEN is currently unprofitable.
Growing Profit Margin: PGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: PGEN has a negative Return on Equity (-84.89%), as it is currently unprofitable.
How is Precigen's financial position?
Financial Position Analysis
Short Term Liabilities: PGEN's short term assets ($153.1M) exceed its short term liabilities ($29.0M).
Long Term Liabilities: PGEN's short term assets ($153.1M) do not cover its long term liabilities ($216.7M).
Debt to Equity History and Analysis
Debt Level: PGEN's net debt to equity ratio (50.1%) is considered high.
Reducing Debt: PGEN's debt to equity ratio has increased from 1.5% to 137.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PGEN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PGEN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 14% each year.
What is Precigen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Helen Sabzevari (59 yo)
Dr. Helen Sabzevari, Ph D., MPH, serves as Director at Kinnate Biopharma Inc. since June 2021. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intrexon Corporation) since Janu...
CEO Compensation Analysis
Compensation vs Market: Helen's total compensation ($USD20.41M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.
Experienced Management: PGEN's management team is considered experienced (3.8 years average tenure).
Experienced Board: PGEN's board of directors are seasoned and experienced ( 10 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.5%.
Precigen, Inc.'s employee growth, exchange listings and data sources
- Name: Precigen, Inc.
- Ticker: PGEN
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$814.550m
- Shares outstanding: 206.74m
- Website: https://www.precigen.com
Number of Employees
- Precigen, Inc.
- 20374 Seneca Meadows Parkway
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/01 00:05|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.